SCHEMBL24258095

SCHEMBL24258095

CN1CCC(n2cc(Nc3ncc(Cl)c(NCC4CCOCC4)n3)cn2)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 12/20 0.57
JAK1 P23458 10/20 0.57
JAK2 O60674 10/20 0.52
TYK2 P29597 5/20 0.51
TNK2 Q07912 4/20 0.51
CHEK1 O14757 1/20 0.51
ABL1 P00519 1/20 0.51
LCK P06239 1/20 0.51
ROS1 P08922 1/20 0.51
FGFR1 P11362 1/20 0.51
SRC P12931 1/20 0.51
ALK Q9UM73 1/20 0.51
FLT4 P35916 2/20 0.49
KDR P35968 2/20 0.49
MAP3K7 O43318 1/20 0.47
MAPK1 P28482 1/20 0.47
MAP2K1 Q02750 1/20 0.47
LRRK2 Q5S007 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258129 0.93 JAK3 (0.65) JAK3JAK1JAK2TYK2TNK2
SCHEMBL26361468 0.90 JAK3 (0.60) JAK3JAK1JAK2TYK2TNK2
SCHEMBL15071983 0.86 JAK2 (0.58) JAK3JAK1JAK2TYK2TNK2
SCHEMBL22635157 0.82 ULK1 (0.52) JAK3JAK1JAK2TYK2TNK2
SCHEMBL29490474 0.82 ULK1 (0.52) JAK3JAK1JAK2TYK2TNK2
SCHEMBL24255327 0.81 TNK2 (0.62) JAK2TYK2TNK2CHEK1ABL1
SCHEMBL24255222 0.81 TNK2 (0.75) JAK2TYK2TNK2CHEK1ABL1
SCHEMBL24258126 0.79 TNK2 (0.61) JAK2TYK2TNK2CHEK1ABL1
SCHEMBL22635441 0.79 TBK1 (0.46) JAK3JAK1JAK2TYK2TNK2
SCHEMBL29490560 0.79 TBK1 (0.46) JAK3JAK1JAK2TYK2TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303499-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH 2023-09-28 US disclosed
US-20230303499-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE NATIONAL INSTITUTES OF HEALTH 2023-09-28 US disclosed
WO-2022036310-A2 INHIBITORS OF ACK1/TNK1 TYROSINE KINASE H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303499-A1 INHIBITORS OF ACK1/TNK2 TYROSINE KINASE TNK1, TNK2, TNNI3K JAK3 500/4885JAK1 594/4885JAK2 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.